NCT03909282 2026-03-12
NORDIS
Stanford University
Phase NA Recruiting
Clinical Trials
16 trialsNCT05325632 2026-03-02
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05505643 2026-02-27
COOL-IT
Washington University School of Medicine
Phase NA Recruiting
NCT07053085 2026-02-27
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06291064 2026-02-17
TARMAC
University of Chicago
Phase 2 Recruiting
NCT06635980 2025-12-12
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06092892 2025-12-10
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT03546686 2025-10-27
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT05919108 2025-09-09
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT06839001 2025-06-26
CRYSTAL - SIX
Hospital do Coracao
Phase 3 Recruiting
NCT06209099 2025-06-12
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT06496659 2024-11-14
SAINT
Northwestern University
Phase NA Recruiting
NCT06634966 2024-10-10
Segmentectomy for Solid-dominant Lung Cancer
Fudan University
Phase 3 Recruiting
NCT04937283 2024-06-17
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
Shanghai Pulmonary Hospital, Shanghai, China
Phase NA Recruiting
NCT05717803 2024-06-03
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
Fudan University
Phase 3 Recruiting
NCT05772923 2023-03-17
OPAXX
The Netherlands Cancer Institute
Phase NA Recruiting